KR101660360B1 - Ｃ형 간염 치료용 우라실 또는 티민 유도체 - Google Patents
Ｃ형 간염 치료용 우라실 또는 티민 유도체 Download PDFInfo
- Publication number
- KR101660360B1 KR101660360B1 KR1020157010052A KR20157010052A KR101660360B1 KR 101660360 B1 KR101660360 B1 KR 101660360B1 KR 1020157010052 A KR1020157010052 A KR 1020157010052A KR 20157010052 A KR20157010052 A KR 20157010052A KR 101660360 B1 KR101660360 B1 KR 101660360B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- alkyl
- independently selected
- optionally substituted
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1C(N(C(*)C(*)C(N2*)=O)C2=O)=CC(*)=C(*)C1C(*)=C(*)* Chemical compound CC1C(N(C(*)C(*)C(N2*)=O)C2=O)=CC(*)=C(*)C1C(*)=C(*)* 0.000 description 13
- UHMIQMCYZFEWKI-UHFFFAOYSA-O CC(C)(C(OC)=O)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc(cc(cc3)NS(C)(=O)=O)c3c2)c1[OH+]C Chemical compound CC(C)(C(OC)=O)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc(cc(cc3)NS(C)(=O)=O)c3c2)c1[OH+]C UHMIQMCYZFEWKI-UHFFFAOYSA-O 0.000 description 1
- QZWYUUSYTBPGGN-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c(cc2)cc3c2[s]c(N)n3)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c(cc2)cc3c2[s]c(N)n3)c1OC QZWYUUSYTBPGGN-UHFFFAOYSA-N 0.000 description 1
- JAESXJLAMBRTBM-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c(cc2CC3)ccc2N3S(C)(=O)=O)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c(cc2CC3)ccc2N3S(C)(=O)=O)c1OC JAESXJLAMBRTBM-UHFFFAOYSA-N 0.000 description 1
- OIOOUZKXUXQCIF-QFIPXVFZSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc([C@H](CC3)C(C)(C)NS(C)(=O)=O)c3c2)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc([C@H](CC3)C(C)(C)NS(C)(=O)=O)c3c2)c1OC OIOOUZKXUXQCIF-QFIPXVFZSA-N 0.000 description 1
- DSBZMFBIBUTQAU-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc(c(CNS(C)(=O)=O)c[o]3)c3c2)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c2ccc(c(CNS(C)(=O)=O)c[o]3)c3c2)c1OC DSBZMFBIBUTQAU-UHFFFAOYSA-N 0.000 description 1
- WZXHXAMWFDIQQO-BQYQJAHWSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(/C=C/c(c(C)c2)cc(F)c2NS(C)(=O)=O)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(/C=C/c(c(C)c2)cc(F)c2NS(C)(=O)=O)c1OC WZXHXAMWFDIQQO-BQYQJAHWSA-N 0.000 description 1
- DLCHOHXVKAYPGB-MOSHPQCFSA-N CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(/C=C(/c(cc2)ccc2NS(C)(=O)=O)\F)c1OC Chemical compound CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(/C=C(/c(cc2)ccc2NS(C)(=O)=O)\F)c1OC DLCHOHXVKAYPGB-MOSHPQCFSA-N 0.000 description 1
- JJOQBONMMNFIBP-UHFFFAOYSA-N CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(C#Cc(c(C)c2)ccc2NS(C)(=O)=O)c1OC Chemical compound CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(C#Cc(c(C)c2)ccc2NS(C)(=O)=O)c1OC JJOQBONMMNFIBP-UHFFFAOYSA-N 0.000 description 1
- MQYIPJLZVCEUNC-UHFFFAOYSA-N CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(C#Cc(ccc(NS(C)(=O)=O)c2)c2Cl)c1 Chemical compound CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(C#Cc(ccc(NS(C)(=O)=O)c2)c2Cl)c1 MQYIPJLZVCEUNC-UHFFFAOYSA-N 0.000 description 1
- ALTCVWWPLSVNPO-UHFFFAOYSA-N CC(C1C=CC(c(cc(cc2NS(C)(=O)=O)N(C=CC3OC3N3)C3=O)c2OC)=CC1C=C1)C=C1NS(C)(=O)=O Chemical compound CC(C1C=CC(c(cc(cc2NS(C)(=O)=O)N(C=CC3OC3N3)C3=O)c2OC)=CC1C=C1)C=C1NS(C)(=O)=O ALTCVWWPLSVNPO-UHFFFAOYSA-N 0.000 description 1
- QWTBFAAAGKUSHJ-UHFFFAOYSA-N CC1c(cc(cc2)NS(C)(=O)=O)c2SC(c2cc(N(CCC(N3)=O)C3=O)cc(C(C)(C)C)c2OC)=CC1 Chemical compound CC1c(cc(cc2)NS(C)(=O)=O)c2SC(c2cc(N(CCC(N3)=O)C3=O)cc(C(C)(C)C)c2OC)=CC1 QWTBFAAAGKUSHJ-UHFFFAOYSA-N 0.000 description 1
- OWWLETRKJWPVSI-UHFFFAOYSA-N CCCC(OCN(c(cc1)ccc1NC(c(cc(cc1C(C)(C)C)N(CCC(N2COC(CCC)=O)=O)C2=O)c1OC)=O)S(C)(=O)=O)=O Chemical compound CCCC(OCN(c(cc1)ccc1NC(c(cc(cc1C(C)(C)C)N(CCC(N2COC(CCC)=O)=O)C2=O)c1OC)=O)S(C)(=O)=O)=O OWWLETRKJWPVSI-UHFFFAOYSA-N 0.000 description 1
- JTRQHRROGPCQHE-UHFFFAOYSA-N COC(c1cc(N(C=CC(N2)=O)C2=O)cc(-c(ccc2c3)cc2ccc3NS(C)(=O)=O)c1OC)=O Chemical compound COC(c1cc(N(C=CC(N2)=O)C2=O)cc(-c(ccc2c3)cc2ccc3NS(C)(=O)=O)c1OC)=O JTRQHRROGPCQHE-UHFFFAOYSA-N 0.000 description 1
- HCLWAHMYNIGJBD-UHFFFAOYSA-N COc(c(-c1ccc[s]1)c1)c(C2C=CC(C(CNS(C)(=O)=O)=CC3)=C3C2)cc1N(C=CC(N1)=O)C1=O Chemical compound COc(c(-c1ccc[s]1)c1)c(C2C=CC(C(CNS(C)(=O)=O)=CC3)=C3C2)cc1N(C=CC(N1)=O)C1=O HCLWAHMYNIGJBD-UHFFFAOYSA-N 0.000 description 1
- LLZZVBAQTIOPNB-UHFFFAOYSA-N CS(NCC(CC=C1N)C=C1N)(=O)=O Chemical compound CS(NCC(CC=C1N)C=C1N)(=O)=O LLZZVBAQTIOPNB-UHFFFAOYSA-N 0.000 description 1
- FPBZIBZCYAPODX-UHFFFAOYSA-N CS(NCc(cc1[N+]([O-])=O)ccc1[N+]([O-])=O)(=O)=O Chemical compound CS(NCc(cc1[N+]([O-])=O)ccc1[N+]([O-])=O)(=O)=O FPBZIBZCYAPODX-UHFFFAOYSA-N 0.000 description 1
- IZUKQUVSCNEFMJ-UHFFFAOYSA-N [O-][N+](c1ccccc1[N+]([O-])=O)=O Chemical compound [O-][N+](c1ccccc1[N+]([O-])=O)=O IZUKQUVSCNEFMJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97287707P | 2007-09-17 | 2007-09-17 | |
| US60/972,877 | 2007-09-17 | ||
| US9679108P | 2008-09-13 | 2008-09-13 | |
| US61/096,791 | 2008-09-13 | ||
| PCT/US2008/076576 WO2009039127A1 (en) | 2007-09-17 | 2008-09-17 | Uracil or thymine derivative for treating hepatitis c |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107008431A Division KR101552474B1 (ko) | 2007-09-17 | 2008-09-17 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150117632A KR20150117632A (ko) | 2015-10-20 |
| KR101660360B1 true KR101660360B1 (ko) | 2016-09-27 |
Family
ID=39948002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157010052A Expired - Fee Related KR101660360B1 (ko) | 2007-09-17 | 2008-09-17 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
| KR1020107008431A Active KR101552474B1 (ko) | 2007-09-17 | 2008-09-17 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107008431A Active KR101552474B1 (ko) | 2007-09-17 | 2008-09-17 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
Country Status (30)
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014147354A (ru) | 2007-09-17 | 2015-07-10 | Эббви Бахамаз Лтд. | Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения |
| NZ600371A (en) | 2007-09-17 | 2014-07-25 | Abbvie Bahamas Ltd | Uracil or thymine derivative for treating hepatitis c |
| CN101918369B (zh) * | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN102099351A (zh) * | 2007-11-16 | 2011-06-15 | 先灵公司 | 3-杂环取代的吲哚衍生物及其使用方法 |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2736472A1 (en) | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyrine or pyrazine derivatives for treating hcv |
| CA2753825C (en) * | 2009-03-24 | 2017-10-17 | Abbott Laboratories | Process for preparing substituted pyrimidine antiviral compound |
| MX2011010047A (es) * | 2009-03-25 | 2011-10-11 | Abbott Lab | Compuestos antivirales y usos de los mismos. |
| EP2411007A4 (en) * | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| EP2421831A1 (en) | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| CA2762675A1 (en) | 2009-06-24 | 2010-12-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compound |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| CN102498100A (zh) | 2009-09-21 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
| CA2778206A1 (en) * | 2009-11-21 | 2011-05-26 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2780526A1 (en) | 2009-12-14 | 2011-06-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| MX2012014235A (es) | 2010-07-07 | 2013-01-28 | Hoffmann La Roche | Compuestos hetericiclicos antiviricos. |
| CR20180412A (es) | 2010-07-16 | 2018-11-01 | Abbvie Ireland Unlimited Co | Proceso para preparar compuestos antivirales |
| AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| EP3461556A1 (en) | 2010-07-16 | 2019-04-03 | AbbVie Ireland Unlimited Company | Phosphine ligands for catalytic reactions |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| KR101382730B1 (ko) | 2010-08-13 | 2014-04-08 | 에프. 호프만-라 로슈 아게 | 헤테로환형 항바이러스성 화합물 |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| US9248193B2 (en) | 2011-03-18 | 2016-02-02 | Abbvie Inc. | Formulations of phenyl uracil compounds |
| SG10201602384VA (en) * | 2011-03-31 | 2016-05-30 | Konstanze Schäfer | Perfluorinated compounds for the non-viral transfer of nucleic acids |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | １，３−ジヨードヒダントイン類の製造方法 |
| CN104024241B (zh) | 2011-08-01 | 2016-01-20 | 大日本住友制药株式会社 | 尿嘧啶衍生物和其用于医学目的的用途 |
| AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| EA026559B1 (ru) | 2012-05-15 | 2017-04-28 | Новартис Аг | Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1 |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| CN104379574B (zh) | 2012-05-15 | 2017-03-01 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 |
| HRP20180695T1 (hr) | 2012-05-15 | 2018-06-01 | Novartis Ag | Derivati benzamida za inhibiranje aktivnosti od abl1, abl2 i bcr-abl1 |
| CN104379145A (zh) | 2012-06-27 | 2015-02-25 | 艾伯维公司 | Abt-450和利托那韦和例如abt-072和/或abt-333用于在治疗hcv中使用的联合治疗 |
| WO2014031791A1 (en) | 2012-08-21 | 2014-02-27 | Abbvie Inc. | Process for preparing antiviral compounds |
| AU2013330993B2 (en) | 2012-10-18 | 2018-03-01 | Abbvie Inc. | Formulations of pyrimidinedione derivative compounds |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| CA2916912A1 (en) | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for treating hcv |
| JP6423873B2 (ja) | 2013-07-08 | 2018-11-14 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての６員ｃ−ｎ−結合アリールスルフィド誘導体及びアリールスルホキシド誘導体 |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| EP3099295A1 (en) | 2014-01-28 | 2016-12-07 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| EP3174868B1 (en) | 2014-08-01 | 2021-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
| WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
| MX371304B (es) | 2014-10-14 | 2020-01-24 | Vitae Pharmaceuticals Llc | Dihidropirrolopiridinas inhibidoras del receptor huérfano-gamma. |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
| WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
| WO2017019828A1 (en) * | 2015-07-30 | 2017-02-02 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| AU2016355710B2 (en) | 2015-11-20 | 2021-03-25 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| UA126583C2 (uk) | 2017-07-24 | 2022-11-02 | Вітае Фармасьютікалс, Ллс | ІНГІБІТОРИ ROR<font face="Symbol">g</font> |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| US11613543B2 (en) | 2018-03-26 | 2023-03-28 | Novartis Ag | Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101552474B1 (ko) * | 2007-09-17 | 2015-09-11 | 애브비 바하마스 리미티드 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| US5084084A (en) | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| AU627906B2 (en) | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| CA2036304C (en) | 1990-02-15 | 2001-04-17 | Takehiko Naka | Pyrimidinedione derivatives, their production and use |
| NL9001075A (cg-RX-API-DMAC7.html) | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| CZ303435B6 (cs) | 1999-12-06 | 2012-09-12 | F. Hoffmann-La Roche Ag | 4-Pyrimidinyl-N-acyl-1-fenylalanin, meziprodukt pro jeho prípravu a farmaceutická kompozice |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| IL167955A (en) | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | Inilines are converted by troiril |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| AR061570A1 (es) * | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| RU2014147354A (ru) * | 2007-09-17 | 2015-07-10 | Эббви Бахамаз Лтд. | Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения |
| CN101918369B (zh) * | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
-
2008
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101552474B1 (ko) * | 2007-09-17 | 2015-09-11 | 애브비 바하마스 리미티드 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
Non-Patent Citations (2)
| Title |
|---|
| Chemistry of Heterocyclic Compounds, 18(9), 967-971쪽(1982.)* |
| The Journal of Organic Chemistry, 71(24), 9183-9190쪽(2006.11.24.)* |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101660360B1 (ko) | Ｃ형 간염 치료용 우라실 또는 티민 유도체 | |
| CA2699986C (en) | Anti-infective pyrimidines and uses thereof | |
| AU2014280939B2 (en) | Uracil or thymine derivative for treating hepatitis C | |
| HK1189590A (en) | Anti-infective pyrimidines and uses thereof | |
| HK1189590B (en) | Anti-infective pyrimidines and uses thereof | |
| HK1156033B (en) | Anti-infective pyrimidines and uses thereof | |
| HK1148273B (en) | Anti-infective pyrimidines and uses thereof | |
| AU2013202002A1 (en) | Uracil or thymine derivative for treating hepatitis C | |
| HK1177457B (en) | Anti-infective pyrimidines and uses thereof | |
| HK1177457A (en) | Anti-infective pyrimidines and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 St.27 status event code: A-0-1-A10-A18-div-PA0104 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
Fee payment year number: 1 St.27 status event code: A-2-2-U10-U12-oth-PR1002 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| S17-X000 | Non-exclusive voluntary license recorded |
St.27 status event code: A-4-4-S10-S17-lic-X000 |
|
| A101 | Application to extend term of patent right by permit | ||
| PA0101 | Application to register extension of term of patent right by permit, etc. |
Protection beyond ip right term event data comment text: Claim Total Quantity : 2, Claim Number : 1, 2, Period Limitation Text : 169, Comment Text : 28 St.27 status event code: A-4-4-G10-G18-tex-PA0101 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R14-asn-PN2301 |
|
| PE0702 | Decision to register extension of term of patent right by permit, etc. |
Protection beyond ip right term event data comment text: Claim Total Quantity : 2, Claim Number : 1, 2, Period Limitation Text : 169, Comment Text : 28 St.27 status event code: A-4-4-G10-G20-tex-PE0702 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| FPAY | Annual fee payment |
Payment date: 20190624 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Fee payment year number: 4 St.27 status event code: A-4-4-U10-U11-oth-PR1001 |
|
| PC1903 | Unpaid annual fee |
Not in force date: 20200922 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE St.27 status event code: A-4-4-U10-U13-oth-PC1903 |
|
| PC1903 | Unpaid annual fee |
Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20200922 St.27 status event code: N-4-6-H10-H13-oth-PC1903 |